AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
阿豆学长长ov
发表于 2023-12-26 19:02:07
236
0
0
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to AstraZeneca's cell therapy pipeline, further deepening its layout in the field of cell therapy.
AstraZeneca introduced that GC012F, based on the FasTCAR technology platform, is an innovative BCMA/CD19 dual target autochimeric antigen receptor T cell therapy (CAR-T) in the clinical stage, which is expected to become a new generation treatment plan for multiple myeloma, other types of malignant hematological tumors, and autoimmune diseases (including systemic lupus erythematosus (SLE)).
It is reported that the principle of autologous CAR-T cell therapy is to re edit and modify the patient's own immune T cells to target pathogenic cells for disease treatment. The production and preparation process is complex and time-consuming. The FasTCAR next-day production technology platform of Genxi Biotechnology can not only significantly shorten production time, but also enhance the health status of T cells, which is expected to improve the effectiveness of autologous CAR-T therapy. This technology is also expected to be applied in the treatment of rare diseases in the future.
AstraZeneca's Global Executive Vice President and Head of Research and Development in the Field of Cancer Therapy, Gao Shucan, stated that the company has established CAR-T and TCR-T pipelines for solid tumors. The acquisition of Genxi Biotechnology will further strengthen AstraZeneca's strength in the field of cell therapy. GC012F will help the company accelerate its strategy of laying out cell therapy in the field of blood tumors, and is expected to provide potential treatment options for blood tumor patients with similar differentiated production.
After the acquisition is completed, Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- Cancer company Aravive's US stock market plummeted by over 57% before trading
- Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
-
AIエクスプレスによると、10月3日、米株の人気の中概株盤の前が低くなり、ピッピッピッと5%近く下落し、相多、名創優品、小鵬自動車は3%超下落し、百度、蔚来自動車、京東は2%超下落した。 ...
- SOGO
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏
-
ナスダック中国の金龍指数は5%超上昇し、楽しい自動車は120%超上昇し、金山雲は18%超上昇し、ピシャリと12%超上昇し、子牛の電動、怪獣の充電は10%超上昇し、愛奇芸は8%超上昇し、テンセント音楽、新東方は7%超上昇 ...
- hecgdge4
- 昨天 10:28
- 支持
- 反对
- 回复
- 收藏
-
10月1日、理想自動車が9月に納入したデータによると、9月に理想自動車が新車53709台を納入し、前年同月比48.9%増となった。 今年第3四半期、理想自動車は前年同期比45.4%増の152831台を納入した。今年9月30日現在、 ...
- 就放荡不羁就h
- 前天 12:06
- 支持
- 反对
- 回复
- 收藏
-
EUが中国の電気自動車に関税を課す方針、独首相と財務相が反発 ドイツ連邦のショルツ首相は現地時間の10月2日、EUが中国の電気自動車に一時的な補助金税を課す紛争を解決するために中国と交渉することを表明した。 ...
- 寒郁轩良
- 11 小时前
- 支持
- 反对
- 回复
- 收藏